By vgreene, 14 July, 2020 Proposed mechanism: reduces inflammatory response by reducing release of substance P via inhibition of neurokinin-1 receptors
By switaschek, 14 July, 2020 If significant adverse effect, review risk/benefit to determine if taper or d/c is appropriate. Monitor at least qmo during taper plus ≥4mo post-d/c2
By switaschek, 14 July, 2020 If (-) clinically significant response after 4-wk trial at adequate dose, taper & w/d. Monitor at least qmo during taper plus ≥4mo post-d/c2